Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25529107 | 0.84 | KMT2A (0.40) | KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL25529270 | 0.80 | KDM4E (0.35) | KDM4ETSHRKMT2AMEN1 | |
| SCHEMBL25533295 | 0.79 | KDM4E (0.58) | KDM4ELMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL26967883 | 0.77 | KMT2A (0.54) | KDM4ETSHRKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL22870151 | 0.71 | KDM4E (0.47) | KDM4ELMNAPOLBHTTTSHR | |
| SCHEMBL7477443 | 0.70 | KDM4E (0.61) | KDM4ELMNAPOLBHTTTSHR | |
| SCHEMBL25529268 | 0.69 | USP2 (0.34) | TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL26967907 | 0.67 | KDM4E (0.42) | KDM4ELMNAPOLBKMT2AMEN1 | |
| SCHEMBL474758 | 0.67 | KDM4E (0.47) | KDM4ELMNAPOLBHTTTSHR | |
| SCHEMBL29868162 | 0.66 | POLB (0.41) | KDM4ELMNAPOLBKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | PRKACB, PRKACA, PRKX | KDM4E 3309/4885LMNA 2600/4885POLB 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.